Research location
Trento
Italy
Advertisement
Research activity in Trento
ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 71 trials and 75 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Trento
71 linked trials · page 1 of 2A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28 · 1 site observation
RECRUITING
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.NCT07028853 · 2025-09-28 · 1 site observation
RECRUITING
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154 · 2025-08-19 · 1 site observation
RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22 · 1 site observation
RECRUITING
Clinical-ultrasonographic Assessment of Pulmonary EmphysemaNCT06533371 · 2024-09-04 · 1 site observation
RECRUITING
GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World SettingNCT07583485 · 2024-07-01 · 1 site observation
RECRUITING
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)NCT06312137 · 2024-04-03 · 1 site observation
RECRUITING
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerNCT05950945 · 2023-12-30 · 1 site observation
RECRUITING
Study on the Incidence of Malignant Neoplasms in Patients With Parkinson's Disease and Heterozygous Mutation of the GBA GeneNCT06814431 · 2023-11-23 · 1 site observation
RECRUITING
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate CancerNCT06783127 · 2023-01-01 · 1 site observation
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654 · 2022-12-12 · 1 site observation
RECRUITING
EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly PhaseNCT06894173 · 2022-12-03 · 1 site observation
RECRUITING
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)NCT04916613 · 2022-04-19 · 1 site observation
RECRUITING
PRostate Cancer Plasma Integrative Multi-modal EvaluationNCT06981377 · 2019-05-07 · 1 site observation
RECRUITING
Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer PatientsNCT06473259 · 2016-12-16 · 1 site observation
RECRUITING
Standardized Italian netwoRk Enrolling iNdividuals With Islet-AutoantibodiesNCT07503366 · 2026-05-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerNCT06764485 · 2025-03-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984 · 2024-12-09 · 1 site observation
ACTIVE_NOT_RECRUITING
REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCERNCT06826677 · 2024-07-30 · 1 site observation
COMPLETED
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)NCT05952557 · 2023-10-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.NCT05803395 · 2023-09-12 · 1 site observation
UNKNOWN
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsNCT05551117 · 2023-06-13 · 1 site observation
TERMINATED
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)NCT05288166 · 2022-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast CancerNCT05173103 · 2021-09-24 · 1 site observation
COMPLETED
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)NCT05063786 · 2021-09-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target TherapyNCT05754502 · 2021-07-27 · 1 site observation
UNKNOWN
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)NCT04497844 · 2020-09-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate CancerNCT04100018 · 2020-02-06 · 1 site observation
COMPLETED
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)NCT04227327 · 2020-01-07 · 1 site observation
TERMINATED
Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer PatientsNCT05730647 · 2019-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)NCT03834506 · 2019-05-02 · 1 site observation
COMPLETED
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)NCT03834519 · 2019-05-02 · 1 site observation
COMPLETED
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerNCT03748641 · 2019-01-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)NCT03740165 · 2018-12-18 · 1 site observation
COMPLETED
Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGationNCT03100253 · 2018-03-01 · 1 site observation
TERMINATED
Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)NCT03542461 · 2017-09-25 · 1 site observation
UNKNOWN
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · 2017-07-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02975934 · 2017-06-13 · 1 site observation
COMPLETED
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.NCT02933801 · 2017-03-31 · 1 site observation
TERMINATED
A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyNCT02952534 · 2017-02-15 · 1 site observation
COMPLETED
Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)NCT02987543 · 2017-02-06 · 1 site observation
COMPLETED
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022 · 2016-12-22 · 1 site observation
ACTIVE_NOT_RECRUITING
Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer PatientsNCT03144947 · 2016-11-29 · 1 site observation
UNKNOWN
Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular GeometryNCT02851745 · 2015-07-01 · 1 site observation
COMPLETED
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPCNCT02438007 · 2015-06-01 · 1 site observation
TERMINATED
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)NCT02319837 · 2014-12-17 · 3 site observations
ACTIVE_NOT_RECRUITING
Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate CancerNCT02453009 · 2014-10-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerNCT02003924 · 2013-10-31 · 3 site observations
COMPLETED
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy RegistryNCT01892319 · 2013-09-30 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.